BTK and paronychia: Ibrutinib and other BTK inhibitors are also known to cause various cutaneous manifestations, including cellulitis, neutrophilic dermatoses, ecthyma, lichenoid eruption, onychomadesis, paronychia, pyogenic granuloma (periungual), pityriasis rosacea, and pyoderma gangrenosum.